Tech Company Financing Transactions
Rigel Pharmaceuticals Funding Round
MPM Capital, Alta Partners and Frazier Healthcare Partners joined a $46 million capital raise for Rigel Pharmaceuticals. The round closed on 6/27/2003.
Transaction Overview
Company Name
Announced On
6/27/2003
Transaction Type
Venture Equity
Amount
$46,000,000
Round
Undisclosed
Investors
MPM Capital (Lead Investor) (Nicholas Simon)
Proceeds Purpose
This financing enables us to vigorously pursue our business strategy and to continue to move forward with the clinical development of our lead programs in allergic rhinitis/asthma, hepatitis C and rheumatoid arthritis.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1180 Veterans Blvd.
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Rigel's mission is to become a source of novel, small-molecule drugs to meet large, unmet medical needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Raul Rodriguez
VP - Bus. Development
Joseph Lasaga
VP - General Counsel
Dolly Vance
VP - R & D
Esteban Masuda
Browse more venture capital transactions:
Prev: 6/26/2003: Bermai venture capital transaction
Next: 6/27/2003: MindGuard venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on funding rounds that are announced publicly. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs